Shree Ganesh Remedies Limited held a Board of Directors meeting on August 12, 2026, which commenced at 5:00 PM and concluded at 5:45 PM. The Board considered and approved several items:
Financial Results Approval
The Board approved the Unaudited (Standalone & Consolidated) Financial Results for the quarter ended June 30, 2026. The financial results were submitted pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Standalone Financial Results (₹ in Lakhs)
- Revenue from Operations: ₹1,436.00 (Q1 FY2027) vs ₹2,466.79 (Q1 FY2026)
- Other Income: ₹93.92 (Q1 FY2027) vs ₹66.17 (Q1 FY2026)
- Total Income: ₹1,529.92 (Q1 FY2027) vs ₹2,532.96 (Q1 FY2026)
- Profit before Tax: ₹153.12 (Q1 FY2027) vs ₹459.80 (Q1 FY2026)
- Total Tax Expense: ₹41.11 (Q1 FY2027) vs ₹114.86 (Q1 FY2026)
- Profit after Tax: ₹112.01 (Q1 FY2027) vs ₹344.94 (Q1 FY2026)
- Total Comprehensive Income: ₹113.24 (Q1 FY2027) vs ₹344.62 (Q1 FY2026)
- Basic & Diluted EPS: ₹0.87 per share (Q1 FY2027) vs ₹2.69 per share (Q1 FY2026)
- Paid-up Equity Share Capital: ₹1,283.76 lakhs (Face Value ₹10 each)
Consolidated Financial Results (₹ in Lakhs)
The consolidated results include the company's wholly owned subsidiary SGRL USA INC (with effect from January 8, 2024). The subsidiary contributed total revenue of NIL lakhs, total net profit/(loss) after tax of NIL lakhs, and total comprehensive income/(loss) of (0.01) lakhs for the quarter ended June 30, 2026.
All financial figures for the consolidated entity were identical to the standalone results for the current quarter.
Auditor Appointments
Cost Auditors: Based on the recommendation of the Audit Committee, the Board appointed M/s. M. I. Prajapati & Associates LLP, Cost Accountants, as Cost Auditors for the year 2026-2027 effective from August 12, 2026. The firm is described as a professionally managed consultancy firm based in Ahmedabad with nearly 15 years of experience, offering services including Cost Audit, Cost Consultancy, GST, Income Tax, Company Incorporation & Compliance, Virtual CFO Services, Stock Audit, Fixed Asset Audit, and Management Consultancy.
Scrutinizer Appointment: The Board appointed Mr. Vishal Thawani of M/s. VTSN and Associates LLP, Practicing Company Secretaries, as Scrutinizer for the e-voting process to be conducted at the 31st Annual General Meeting.
Annual General Meeting
The Board approved the Notice for the 31st Annual General Meeting and the Directors Report together with its Annexures for the year ended March 31, 2026.
Auditor Review
Chaudhary Shah & Associates LLP, Chartered Accountants (FRN: 006212C/W100789), issued review reports for both standalone and consolidated financial results. Their review concluded that nothing came to their attention that causes them to believe that the financial results contain any material misstatement, though they note that a review is substantially less in scope than an audit.
Notes to Financial Results
1. The results were reviewed by the Audit Committee and approved by the Board of Directors on August 12, 2026
2. The company is primarily engaged in Bulk Drug Intermediates, which constitutes a single reportable segment
3. EPS for the quarters are not annualized
4. Kamalam Foundation (a Section 8 company) is not considered in consolidation as it is prohibited from distributing profits to members
5. Previous year's figures have been regrouped for comparability